Development of Continuous Glucose Monitoring System Cohort for Personalized Diabetes Prevention and Management Platform

After being informed about the study and potential risks, all patients giving written informed consent wear a continuous glucose monitoring device ("iPro2" professional continuous glucose monitoring, MedtronicⓇ, California, USA) and smart band ("Fitbit Inspire HR", FitbitⓇ, California, USA) for 1 week.

During this period, all patients are tested oral glucose tolerance test and take a standard diet (calorie calculated) at morning.

The patient's data from this study is compared to a predicted values by mathematical analysis model for diabetes prevention.

Inclusion criteria

• Above 18 years old.
• Prediabetes

• Fasting plasma glucose : 100~125mg/dL, fasting is defined as no caloric intake for at least 8 hours.

OR

• 2-hour plasma glucose during 75g oral glucose tolerance test : 140 ~ 199mg/dL

OR

• Glycated hemoglobin(HbA1c) : 5.7~6.4% (39-47mmol/mol)

Exclusion criteria

• with a history of newly diagnosed and treated cancer within the last 5 years
• with a history of hospitalization for active disease within the last 3 months
• with a history of severe cardiovascular disease within the last 3 months
• with a history of steroid treatment in the last 3 months
• people who have had major surgery planned within the last 3 months or who have had surgery within 3 months
• people who are pregnant or have been in the last 3 months after giving birth